• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

    9/1/23 9:00:00 AM ET
    $GENE
    $SXTP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GENE alert in real time by email

    ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/stocks/GENE
    • 60 Degrees Pharmaceuticals (NASDAQ:SXTP): https://www.redchip.com/stocks/SXTP

    About The RedChip Money Report®

    The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Genetic Technologies

    Genetic Technologies ((ASX:GTG, NASDAQ:GENE). A global leader in genomics-based tests in health, wellness and serious disease through its geneType, EasyDNA and AffinityDNA brands. GTG lead the most comprehensive portfolio of genetic tests from Carrier screening and NIPT to the advanced predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company's Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com.

    About 60 Degrees Pharmaceuticals

    60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60P successfully achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60P also collaborates with prominent research organizations in the U.S., Australia and Singapore. 60P's mission has been supported through in-kind funding from the United States Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60P is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/779391/genetic-technologies-limited-and-60-degrees-pharmaceuticals-interviews-to-air-on-the-redchip-money-reportr-on-bloomberg-tv

    Get the next $GENE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GENE
    $SXTP

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $GENE
    $SXTP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Xu Cheryl bought $21,400 worth of shares (13,000 units at $1.65), increasing direct ownership by 32% to 54,078 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/18/24 8:35:59 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $89,755 worth of shares (73,951 units at $1.21), increasing direct ownership by 358% to 94,580 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      12/9/24 5:07:49 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S bought $6,367 worth of shares (7,000 units at $0.91), increasing direct ownership by 51% to 20,629 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      11/21/24 6:14:45 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GENE
    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and CEO Dow Geoffrey S

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:52:30 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO Miller Tyrone

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:51:10 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Dow Geoffrey S was granted 14,394 shares, increasing direct ownership by 15% to 108,974 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/21/25 5:00:27 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GENE
    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

      Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domes

      5/15/25 4:31:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

      WASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), will participate in a scientific discussion on the management and treatment of babesiosis during the April 15–21 Healing Lyme Summit. Babesiosis is a rapidly emerging tick-borne disease often found as a coinfection with Lyme disease. Drawing on decades of experience in anti-infective product development, Dr. Dow will spotlight the growing threat of babesiosis in the United States, its clinical challenges, and the urgent need for increased awareness and improved diagnos

      4/10/25 8:31:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

      WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the signing of a Patent License Agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration ("FDA") for the treatment and prevention of babesiosis. The agreement follows initiation of collaboration between researchers from both organizations

      4/8/25 8:31:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GENE
    $SXTP
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/15/25 3:10:40 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.

      10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

      5/15/25 10:07:28 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by 60 Degrees Pharmaceuticals Inc.

      SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/14/25 2:57:24 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GENE
    $SXTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/14/24 3:37:18 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc.

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      11/13/24 4:01:15 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 60 Degrees Pharmaceuticals Inc. (Amendment)

      SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

      5/7/24 7:19:08 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GENE
    $SXTP
    Financials

    Live finance-specific insights

    See more
    • VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so

      12/2/24 4:05:00 PM ET
      $SXTP
      $VSEE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Nursing Services
    • 60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on

      11/22/24 9:00:00 AM ET
      $CANF
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

      10/11/24 9:00:00 AM ET
      $BIVI
      $BOXL
      $GENE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate

    $GENE
    $SXTP
    Leadership Updates

    Live Leadership Updates

    See more
    • Genetic Technologies Invited to Join Prestigious "CancerIQ" Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics

      MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center

      9/11/24 8:15:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary

      MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited.  More r

      7/16/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • GTG to launch U.S. Customer Digital Media Sales Campaign

      MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG's strategy ensures that the company's geneType Risk Assessment test portfolio will be

      2/28/24 8:00:00 AM ET
      $GENE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care